Discus Dental Secures Exclusive U.S. Distribution Rights for sole FDA Approved Prescription Drug for Aphthous Ulcers

Breakthrough Product Signals Potential Relief for the Millions of Canker Sore Sufferers in the U.S.

(Culver City, CA), December 6, 2005 – Discus Dental, a leading manufacturer and marketer of professional and consumer dental products, today announced it had reached an agreement with Uluru, Inc. for the exclusive U.S. distribution rights of Aphthasol, the first and only FDA approved prescription drug for the treatment of recurrent aphthous ulcers (canker sores) in healthy adults. The agreement includes distribution through retail pharmacies, institutional pharmacies and direct to medical and dental professionals.

“This agreement will allow us to leverage our strengths within the dental industry to effectively create awareness and adoption of this breakthrough product and provide the millions of canker sore sufferers with a proven treatment,” explained Brendan McLoughlin, Vice President & General Manager of Pharmaceutical & Consumer Products, Discus Dental.

Approximately 60 million people in the U. S. suffer from the pain and irritation of canker sores annually. The exact cause of most canker sores is unknown. Stress or tissue injury is thought to be the cause of simple canker sores. Certain foods – including citrus or acidic fruits and vegetables can trigger a canker sore or make the problem worse. Some cases of complex canker sores are caused by an underlying health condition, such as an impaired immune system; nutritional problems, such as vitamin B-12, zinc, folic acid, or iron deficiency; and gastrointestinal tract disease, such as Celiac disease and Crohn's disease.

“With their exceptional record marketing products to the dental professionals and their consumer marketing expertise Discus Dental is the ideal partner to market Aphthasol,” says Kerry Gray, President and CEO of ULURU Inc. “Extensive market research clearly indicates that there is a significant market opportunity for a product that can accelerate healing of aphthous ulcers and reduce pain. We look forward to working with Discus Dental to maximize this product opportunity.”

Discus Dental: Founded in 1993, Discus Dental, Inc. is a leader in the marketing and worldwide distribution of premium clinical and aesthetic products to dental professionals and leading edge oral care products direct to consumers. The company also provides state of the art practice management software, practice building tools and services as well as expert industry training for the dental community. Discus Dental is headquartered in Culver City, California. More information is available at www.discusdental.com.

Uluru Inc. is an emerging specialty pharmaceutical company dedicated to becoming a leading topical drug delivery and oral care company by developing products utilizing its innovative transmucosal delivery system and hydrogel nanopartical aggregate technology and acquiring value-added topical products.